Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

ABSTRACT:

Background

Sotorasib showed anticancer activity in patients with KRAS p.G12C-mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed in a subgroup of patients with non-small-cell lung cancer (NSCLC).

Methods

In a single-group, phase 2 trial, we investigated the activity of sotorasib, administered orally at a dose of 960 mg once daily, in patients with KRAS p.G12C-mutated advanced NSCLC previously treated with standard therapies. The primary end point was objective response (complete or partial response) according to independent central review. Key secondary end points included duration of response, disease control (defined as complete response, partial response, or stable disease), progression-free survival,

SUBMITTER: Skoulidis F 

PROVIDER: S-EPMC9116274 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature